ImmuCell Corporation (ICCC) News

ImmuCell Corporation (ICCC): $9.73

-0.02 (-0.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ICCC to Watchlist
Sign Up

Industry: Biotech


Ranked

of 481

in industry

Filter ICCC News Items

ICCC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ICCC News Highlights

  • For ICCC, its 30 day story count is now at 2.
  • list("500 - Internal server error")
  • The most mentioned tickers in articles about ICCC are MAR, DECK and SAFE.

Latest ICCC News From Around the Web

Below are the latest news stories about Immucell Corp that investors may wish to consider to help them evaluate ICCC as an investment opportunity.

ImmuCell reports 16% drop in prelim Q1 sales

ImmuCell (ICCC) reported prelim sales for first quarter ended Mar. 31, 2021."We expect to report a 16%, or $791K, decrease in total product sales to ~$4.1M during the quarter ended Mar. 31, 2021 versus the same period of the prior year, during which our sales benefitted from a higher level...

Seeking Alpha | April 7, 2021

ImmuCell Announces Preliminary, Unaudited Sales Results for First Quarter of 2021

PORTLAND, Maine, April 07, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter ended March 31, 2021. Beginning with the first quarter of 2020, the Company has been providing a preliminary look at the top line results early in the reporting period. The Company expects to provide this prompt, preliminary report on product sales until further notice going forward. “We expect to report a 16%, or $791,000, decrease in total product sales to approximately $4.1 million during the quarter ended March ...

Yahoo | April 7, 2021

ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2020

Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ETPORTLAND, Maine, Feb. 16, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, will report unaudited financial results for the year ended December 31, 2020 after the market closes on Monday, February 22, 2021. The Company has scheduled a conference call the next morning, Tuesday, February 23, 2021, at 9:00 AM ET to review the results. Interested parties can access the conference call scheduled by the Company to review the full year 2020 financial results by dialing (844) 855-9502 (toll free) or (412...

Yahoo | February 16, 2021

The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 27) Abbott Laboratories (NYSE: ABT ) (reacted to fourth-quarter results) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Aziyo Biologics Inc (NASDAQ: AZYO ) Cassava Sciences Inc (NASDAQ: SAVA ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Frequency Therapeutics Inc (NASDAQ: FREQ ) (reacted to ratings upgrade by JPMorgan to Overweight) Fulgent Genetics Inc (NASDAQ: FLGT ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Illumina, Inc. (NASDAQ: ILMN ) ImmuCell Corporation (NASDAQ: ICCC ) I...

Benzinga | January 28, 2021

ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2020

PORTLAND, Maine, Jan. 07, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company…

GlobeNewswire | January 7, 2021

ImmuCell Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2020

PORTLAND, Maine, Nov. 12, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, today announced unaudited financial results for the quarter ended September 30, 2020.Product Sales Results: * Total product sales increased by 25%, or $752,000, to $3.7 million during the three-month period ended September 30, 2020 versus the comparable period during 2019. * The backlog of orders was reduced to approximately $130,000 as of September 30, 2020 from approximately $945,000 as of June 30, 2020. * During the nine-month period ended September 30, 2020, total product sales incre...

Yahoo | November 12, 2020

The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 11) * Beam Therapeutics Inc (NASDAQ: BEAM) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) * Denali Therapeutics Inc (NASDAQ: DNLI) * Fate Therapeutics Inc (NASDAQ: FATE) * Five Prime Therapeutics Inc (NASDAQ: FPRX) (announced positive midstage stomach cancer study) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Inspire Medical Systems Inc (NYSE: INSP) * Kura Oncology Inc (NASDAQ: KURA) * Kymera Therapeutics Inc (NASDAQ: KYMR) * MannKind Corporation (NASDAQ: MNKD) * Merit Medical Systems, Inc. (NASDAQ: MMSI) * Neuronetics Inc (NASDAQ: STIM) * OncoSec Medical Inc (NASDAQ: ONCS) * Pac...

Yahoo | November 12, 2020

ImmuCell to Announce Unaudited Financial Results for Third Quarter of 2020

Conference Call Scheduled for Friday, November 13, 2020 at 9:00 AM ET

GlobeNewswire | November 5, 2020

Contrasting Fuse Science (OTCMKTS:DROP) and ImmuCell (OTCMKTS:ICCC)

Fuse Science (OTCMKTS:DROP) and ImmuCell (NASDAQ:ICCC) are both consumer staples companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends. Volatility and Risk Fuse Science has a beta of 0.52, indicating that its share price is […]

Dakota Financial News | October 24, 2020

Fuse Science (OTCMKTS:DROP) versus ImmuCell (OTCMKTS:ICCC) Head-To-Head Analysis

Fuse Science (OTCMKTS:DROP) and ImmuCell (NASDAQ:ICCC) are both consumer staples companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends. Insider & Institutional Ownership 9.3% of ImmuCell shares are held by institutional investors. 7.2% of Fuse […]

The Lincolnian | October 21, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8678 seconds.